DB Power and LPA announce strategic partnership to globally expand solutions for issuers of structured retail products

Real Time Search
CES A80 :
CES HKMI :
CES 120 :
Total Turn.

02637 HAIXI PHARMA

Closed Add to Porfolio
Index Constituent : None
Major Shareholders Kang Xinshan (35.16%)
Tu Liandong & Associates (20.33%)
Fujian Province Investment Development Group Co., Ltd. (8.89%)
Fuzhou Financial Holding Group Co., Ltd. (5.95%)		 Sector Health Care & Biotechnology
Web Site http://www.hxpharma.com Tel (86 0591) 8751-9936
Email info@hxpharma.com Fax N/A
Related Equities N/A
Principal Activities The Group engages in the businesses of research and development, and manufacture and sale of pharmaceutical products.

Consolidated List of Substantial Shareholders

Name Number of Shares Interested % of Issued Share Capital (%) Date of Last Notice Filed (Y/M/D)
Last Update :
Note : (L) - Long Position (S) - Short Position (P) - Lending Pool

Complete List of Directors

Director's Name Number of Shares Interested % of issued share capital (%) Date of Last Notice Filed (Y/M/D)
Last Update :
Note : (L) - Long Position (S) - Short Position (P) - Lending Pool
Back to Top